Sort   by:  
 Page size 
UnknownImproved survival after transplantation of more donor plasmacytoid dendritic or naive T cells from unrelated-donor marrow grafts: results from BMTCTN 0201.
Not available
S-EPMC4180368 | biostudies-literature
UnknownPhase II Study of Allogeneic Transplantation for Older Patients With Acute Myeloid Leukemia in First Complete Remission Using a Reduced-Intensity Conditioning Regimen: Results From Cancer and Leukemia Group B 100103 (Alliance for Clinical Trials in Oncology)/Blood and Marrow Transplant Clinical Trial Network 0502.
Not available
S-EPMC4658453 | biostudies-literature
UnknownMyeloablative Versus Reduced-Intensity Hematopoietic Cell Transplantation for Acute Myeloid Leukemia and Myelodysplastic Syndromes.
Not available
S-EPMC5455603 | biostudies-literature
UnknownDisabling immune tolerance by programmed death-1 blockade with pidilizumab after autologous hematopoietic stem-cell transplantation for diffuse large B-cell lymphoma: results of an international phase II trial.
Not available
S-EPMC4878008 | biostudies-literature
UnknownExpanding donor options: haploidentical transplant recipients are also highly likely to have a 7/8-matched unrelated donor.
Not available
S-EPMC10847856 | biostudies-literature
UnknownClinical and pharmacodynamic activity of bortezomib and decitabine in acute myeloid leukemia.
Not available
S-EPMC3383015 | biostudies-literature
UnknownVedolizumab for prevention of graft-versus-host disease after allogeneic hematopoietic stem cell transplantation.
Not available
S-EPMC6963235 | biostudies-literature
UnknownOptimized phenotyping of complex morphological traits: enhancing discovery of common and rare genetic variants.
Not available
S-EPMC11891655 | biostudies-literature
ProteomicsGlobal analysis of cancer cell responses to USP9X inhibition
Mass spectrometry-based 3X-FLAG-Ub-VS deubiquitinase (DUB) competition assay with cell extracts (DUB IP-MS) profiling MCF-7 cells with regard to specificity of WEHI-092, a selective inhibitor for USP9X. Sample key: #1-5 Untreated; #6-10 Ub-VS pre-treatment; #11-15 WEHI-092 treated (50 µM, 60 min).
ORGANISM(S): Homo sapiens (Human) 
2026-04-09 | PXD074545 | Pride
ProteomicsGlobal analysis of cancer cell responses to USP9X inhibition
HDX-MS experiment using selective USP9X inhibitors WEHI-092, FT709 with recombinant catalytic domain USP9X.
ORGANISM(S): Homo sapiens (Human) 
2026-04-09 | PXD062754 | Pride
Sort   by:  
 Page size